Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
The Lancet (2021) - Comments
doi: 10.1016/s0140-6736(21)00461-x  issn: 0140-6736  pubmed: 33676597  issn: 1474-547x 

Christopher C Butler, Jienchi Dorward, Ly-Mee Yu, Oghenekome Gbinigie, Gail Hayward, Benjamin R Saville, Oliver Van Hecke, Nick Berry, Michelle Detry, Christina Saunders, Mark Fitzgerald, Victoria Harris, Mahendra G Patel, Simon De Lusignan, Emma Ogburn, Philip H Evans, Nicholas PB Thomas, FD Richard Hobbs